Multicentre, open label, randomised, controlled trial of severe ARF management with an augmented vs normal CRRT regimen

使用增强与正常 CRRT 方案治疗严重 ARF 的多中心、开放标签、随机、对照试验

• 批准号: nhmrc : 352550
• 负责人: A/Pr Carlos Scheinkestel
• 金额: $ 125.3万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/multicentre-open-label-crrt-regimen/78183
• 关键词: Multicentre; open; label; randomised; controlled

Sudden serious kidney failure is a major problem that frequently occurs in patients who are in Intensive Care. For these patients, their chances of survival are significantly decreased. In Australia sudden serious kidney failure is usually treated with continuous kidney support by a kidney machine. A recent study found that by using greater than normal levels of kidney support, that is , running larger volumes of fluid through the kidney machine, patients in Intensive Care Units (ICU's) may be less likely to die from their sudden serious kidney failure. Despite these positive findings, this high level of kidney support is not commonly used in Australian ICU's. Clearly though, if greater than normal levels of kidney support do increase the chances that individuals will live, then patients should be receiving this treatment. The Australia and New Zealand Intensive Care Society, in conjunction with The George Institute for International Health, propose to conduct a new study involving 1500 patients from ICU's throughout Australia, who require continuous kidney support due to sudden serious kidney failure. These patients will be randomly assigned so that half receive the normally used levels of kidney support and the other half receive kidney support at greater than normal levels. Patients will then be followed for three months to compare the proportions of patients who die in each group. All other outcomes and serious side effects will be closely monitored throughout the study. The results will be available to the public within four years of starting the study, and these are likely to influence the treatment of patients admitted to ICU's with sudden serious kidney failure, not only in Australia but also worldwide.

突发性严重肾功能衰竭是重症监护室患者经常出现的主要问题。对于这些患者来说，他们的生存机会显著降低。在澳大利亚，突发的严重肾功能衰竭通常由肾脏机器进行持续的肾脏支持治疗。最近的一项研究发现，通过使用比正常水平更高的肾脏支持，即通过肾脏机器输送更多的液体，重症监护病房(ICU)的患者可能不太可能死于突然发生的严重肾衰竭。尽管有这些积极的发现，这种高水平的肾脏支持在澳大利亚的ICU中并不常用。但显然，如果高于正常水平的肾脏支持确实增加了个体存活的机会，那么患者应该接受这种治疗。澳大利亚和新西兰重症监护协会与乔治国际卫生研究所合作，提议进行一项新的研究，涉及澳大利亚各地ICU的1500名患者，这些患者因突发的严重肾功能衰竭而需要持续的肾脏支持。这些患者将被随机分配，其中一半接受正常水平的肾脏支持，另一半接受高于正常水平的肾脏支持。然后，将对患者进行为期三个月的跟踪，以比较每组患者的死亡比例。在整个研究过程中，将密切监测所有其他结果和严重副作用。研究结果将在开始研究的四年内向公众公布，这些结果可能会影响不仅在澳大利亚，而且在全球范围内住进ICU的突发性严重肾衰竭患者的治疗。